Crescita Therapeutics Inc (CTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Crescita Therapeutics Inc (CTX) has a cash flow conversion efficiency ratio of 0.027x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$416.00K ≈ $300.93K USD) by net assets (CA$15.58 Million ≈ $11.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CTX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Crescita Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Crescita Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Crescita Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Crescita Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
hGears AG
XETRA:HGEA
|
-0.050x |
|
Perfect Moment Ltd.
NYSE MKT:PMNT
|
2.134x |
|
Holand og Setskog Sparebank
OL:HSPG
|
0.251x |
|
Bonk, Inc.
NASDAQ:BNKK
|
-0.058x |
|
Revenue Group Bhd
KLSE:0200
|
0.178x |
|
Palash Securities Limited
NSE:PALASHSECU
|
-0.045x |
|
K-Tig Ltd
AU:KTG
|
0.748x |
|
Knusford Bhd
KLSE:5035
|
0.011x |
Annual Cash Flow Conversion Efficiency for Crescita Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Crescita Therapeutics Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Crescita Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$15.58 Million ≈ $11.27 Million |
CA$1.07 Million ≈ $776.19K |
0.069x | -59.98% |
| 2024-12-31 | CA$15.83 Million ≈ $11.45 Million |
CA$2.73 Million ≈ $1.97 Million |
0.172x | +56.08% |
| 2023-12-31 | CA$18.82 Million ≈ $13.62 Million |
CA$2.08 Million ≈ $1.50 Million |
0.110x | +328.12% |
| 2022-12-31 | CA$21.10 Million ≈ $15.26 Million |
CA$-1.02 Million ≈ $-737.85K |
-0.048x | +37.86% |
| 2021-12-31 | CA$20.53 Million ≈ $14.85 Million |
CA$-1.60 Million ≈ $-1.16 Million |
-0.078x | -129.32% |
| 2020-12-31 | CA$21.13 Million ≈ $15.29 Million |
CA$5.61 Million ≈ $4.06 Million |
0.265x | +5.57% |
| 2019-12-31 | CA$21.11 Million ≈ $15.27 Million |
CA$5.31 Million ≈ $3.84 Million |
0.251x | +423.27% |
| 2018-12-31 | CA$19.01 Million ≈ $13.75 Million |
CA$-1.48 Million ≈ $-1.07 Million |
-0.078x | +86.23% |
| 2017-12-31 | CA$13.11 Million ≈ $9.48 Million |
CA$-7.40 Million ≈ $-5.35 Million |
-0.565x | +18.50% |
| 2016-12-31 | CA$26.81 Million ≈ $19.39 Million |
CA$-18.58 Million ≈ $-13.44 Million |
-0.693x | -116.76% |
| 2015-12-31 | CA$-3.37 Million ≈ $-2.43 Million |
CA$-13.92 Million ≈ $-10.07 Million |
4.135x | -6.57% |
| 2014-12-31 | CA$-2.10 Million ≈ $-1.52 Million |
CA$-9.30 Million ≈ $-6.73 Million |
4.426x | -- |
About Crescita Therapeutics Inc
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. It operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The company owns proprietary drug delivery platforms, which include Multiplexed Molecular Penetration Enhanc… Read more